UMN Pharma Inc. today announced Phase II clinical trial results for UMN-0501, UMN Pharma's avian influenza A (H5N1) vaccine manufactured by cell-culture. Trial results confirmed that UMN-0501 provided dose-dependent immunogenicity against a wild-type strain of avian influenza A (H5N1) virus. There is no serious adverse event and severe systemic adverse event during the study period. UMN-0501 was well tolerated up to 135µg, please see here